IN VITRO DATA

Buxus Sempervirens inhibits viral replication.
Also it suppresses TNF-a production (Arcopharma, 1994e).

 IN VIVO DATA

			Duration (weeks)	Type of Study	Principal Markers and Study stage (F)	Starting CD4 (mm3) and/or Stage	Starting Viral Load(CV) (copies/ml)	Results	Treated	Controls	Total treated cases
Reference		Dosage
Durant 1994	990 mg/die os vs pl		30	SCC	CD4. (F=I/II)	> 250, CDC= II-III		á CD4	22	21
Stokes 1996b [Pharo 1996; report on 173 out of 400]	990 mg/die os, w/ antiretr. drugs from 6 months bef. SPV30.		4	SA	CD4, CD8, CV	CD4 fra 0 e 860 CD8 fra 42 e 3269	CV tra 0 e 2ML	â CV; for half of participants á CD4 e CD8	400   [173]
Durant 1996	990 mg/die os (1) o 1980 mg/die os (2) vs placebo (3)		37	SCC	CD4, CV, Drop out due to therap. failure. (F=II)	250-500: median 352 (1); 350 (2); 344 (3).	850-53141: Median: 34204 (1); 26573 (2); 26808 (3)	Per SPV 990 mg/die: â CV; excepted for therapeutical failure ; no difference in CD4	48   (1) 47 (2)	48   (3)
											517

Clinical Data - Legenda
DNR = Data Not Available X = Media
M = Improves A = Years Me = Median
S = Synthesis N = Natural SN = Permanently
CC = Clinical Casuistics Negative
Q = Questionnaire S = Stabiliser
SCC = Controlled Cl. Study SA = Open Study
SO = Observational Study SC = Clinical Study
 
 
 

Considerations:

• Buxus is a plant which can be toxic. At the dosage used in SPV-30Ò , it results safe in vitro and in the experiments on men up to now.
• In the studies conducted up to now, SPV-30Ò seems to be able of influencing the clinical course of HIV infection.
• The action mechanism of SPV-30Ò in HIV infection is still not clearly known.

Riferimenti bibliografici

Arkopharma (1994a)
Reverse Mutation Assay "Ames test" Using Salmonella Typhi Murium.
Dossier ad uso interno dei ricercatori. Non pubblicato

Arkopharma (1994b)
Micronucleus Test by Oral Route in Mice.
Dossier ad uso interno dei ricercatori. Non pubblicato

Arkopharma (1994c)
Dossier Toxicologique. Etudes d’innocuité.
Dossier ad uso interno dei ricercatori. Non pubblicato

Arkopharma (1994d)
Etude preliminaire de 14 jours de détermination des doses en vue de la realisation d’une étude par administration reiterée chez le rat par voie orale pendant 28 jours.
Dossier ad uso interno dei ricercatori. Non pubblicato

Arkopharma (1994e)
SPV Project.
Dossier ad uso interno dei ricercatori. Non pubblicato

Arkopharma (1994f)
Etude multicentrique randomisée en double aveugle versus placebo évaluant l’efficacité et la tolérance du SPV 94-AR 01 chez les patients séropositifs V.I.H. asymptomatiques
Arkopharma. Testo di Protocollo sperimentale.

ATN 1997
SPV-30: FDA Stop Distribution Over Advertising
Aids Treat News n° 267: 3

Durant J e al (1994)
Etude randomisée en double aveugle de l’efficacité et de la tolerance du SPV dans le traitement de l’infection VIH chez le patients asymptomatiques.
Arkopharma, non pubblicato; Rapporto sullo studio in questione.

Durant J e al (1996)
A multicenter, randomized, double-blind, placebo-controlled trial of SPV efficacy and safety in HIV-infected asymptomatic patients.
XI Int Conf AIDS Vancouver, Abs B6040

GMHC 1997
SPV-30 Promos Nixed by FDA
GMHC Treatment Issues, vol 11(4/5): 7

Impastato DG (1995)
Boxwood Exstract Shows Promise as an HIV Antiviral: Interview with Dr. Patricia Salvato.
Uptown Expres. Ottobre-Novembre 1995

Pharo A (1996)
Evaluation of the Safety and Efficacy of SPV-30 (Boxwood Extract) in Patients with HIV Disease.
XI Int Conf Aids Vancouver 1996 (Abs Mo.B180)

Stokes CD (1996a)
SPV30, Antiviral Herb
Pos Nat, vol 2(1): 22-24

Stokes CD, Mestman B (1996b)
SPV-30: An Activist Initiated, Informal Study to Collect Data to Determine the Efficacy of a Natural, Alternative Therapy for HIV/AIDS.
XI Int Conf Aids Vancouver, Abs Tu.D2946